Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

Multiple Sclerosis

Volumn 21, Issue 14, 2015, Pages 1823-1832

  Kohlmann, Rebekka ^a   Salmen, Anke ^a   Chan, Andrew ^a   Knabbe, Cornelius ^b   Diekmann, Jürgen ^b   Brockmeyer, Norbert ^a   Skaletz Rorowski, Adriane ^a   Michalik, Claudia ^c   Gold, Ralf ^a   Überla, Klaus ^a,d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Clinical Trials Center   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adverse events; antibodies; autoimmune disease; blood donors; herpes zoster; human immunodeficiency virus; immunosuppression; JC virus; multiple sclerosis; natalizumab; neurotropic virus; risk factors; subclinical reactivation; varicella zoster virus; virus reactivation

Indexed keywords

BIOLOGICAL MARKER; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; NATALIZUMAB; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; REINFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; BLOOD; DRUG EFFECTS; HERPES ZOSTER; IMMUNOLOGY; VIRUS ACTIVATION; YOUNG ADULT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION SENSITIVITY; MEDICAL RECORD REVIEW; NEPHELOMETRY; SEROLOGY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; DISEASE SUSCEPTIBILITY; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84948152876     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515576984     Document Type: Article

References (39)

1. Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005; 204: 208-231.
2. Wingerchuk DM, Carter JL,. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89: 225-240.
3. Rice GP, Hartung HP, Calabresi PA,. Anti-alpha-4 integrin therapy for multiple sclerosis: Mechanisms and rationale. Neurology 2005; 64: 1336-1342.
4. Koudriavtseva T, Sbardella E, Trento E, et al. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol 2014; 176: 320-326.
5. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
6. Tavazzi E, White MK, Khalili K,. Progressive multifocal leukoencephalopathy: Clinical and molecular aspects. Rev Med Virol 2012; 22: 18-32.
7. Biogen Idec. PML-Inzidenz unter Tysabri® nach Marktzulassung. Patientenregister, www.tysabri.de. (2013,. accessed 30 September 2013).
8. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
9. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78: 1736-1742.
10. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
11. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
12. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol 2014; 13: 545-556.
13. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
14. Ratchford JN, Costello K, Reich DS, et al. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012; 79: 2002-2004.
15. Fine AJ, Sorbello A, Kortepeter C, et al. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013; 57: 849-852.
16. Shenoy ES, Mylonakis E, Hurtado RM, et al. Natalizumab and HSV meningitis. J Neurovirol 2011; 17: 288-290.
17. Yeung J, Cauquil C, Saliou G, et al. Varicella-Zoster Virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 80: 1812-1813.
18. Fragoso YD, Brooks JB, Gomes S, et al. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther 2013; 19: 280-281.
19. Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012; 18: 909-911.
20. Bourre B, Lefaucheur R, Ahtoy P, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 2013; 81: 1966-1967.
21. Kobeleva X, Wegner F, Brunotte I, et al. Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. J Neuroinflamm 2014; 11: 19.
22. Ricklin ME, Lorscheider J, Waschbisch A, et al. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 2013; 81: 174-181.
23. Wutzler P, Farber I, Wagenpfeil S, et al. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001; 20: 121-124.
24. Quinlivan M, Breuer J,. Molecular studies of varicella zoster virus. Rev Med Virol 2006; 16: 225-250.
25. Kawai K, Gebremeskel BG, Acosta CJ,. Systematic review of incidence and complications of herpes zoster: Towards a global perspective. Brit Med J Open 2014; 4: e004833.
26. Blank LJ, Polydefkis MJ, Moore RD, et al. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr 2012; 61: 203-207.
27. Jansen K, Haastert B, Michalik C, et al. Incidence and risk factors of herpes zoster among HIV-positive patients in the german competence network for HIV/AIDS (KompNet): A cohort study analysis. BMC Infect Dis 2013; 13: 372.
28. Amanna IJ, Carlson NE, Slifka MK,. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
29. Whitley RJ,. Varicella-Zoster Virus infections. In: Longo DL, Kasper DL, Jameson JL, et al. (eds) Harrison's principles of internal medicine: Volumes 1 and 2. 18th ed. New York: McGraw-Hill Professional, 2011, pp. 1462-1466.
30. Gershon AA, LaRussa P, Steinberg SP., Varicella-zoster virus. In: Murray PR, Baron EJ, Pfaller MA, et al. (eds) Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press, 1999, pp. 900-911.
31. Jansen K, Brockmeyer NH, Hahn M, et al. Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS. Eur J Med Res 2009; 14: 415-425.
32. Stuke K, Flachenecker P, Zettl UK, et al. Symptomatology of MS: Results from the German MS Registry. J Neurol 2009; 256: 1932-1935.
33. Arvin AM, Prober CG,. Herpes simplex viruses. In: Murray PR, Baron EJ, Pfaller MA, et al. (eds) Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press, 1999, pp. 878-887.
34. Kangro HO, Harper DR,. The Herpesviridae: Varicella zoster. In: Zuckerman AJ, Banatvala JE, Pattison JR,. (eds) Principles and practice of clinical virology. 3rd ed. Chichester: John Wiley and Sons, 1994, pp. 37-68.
35. Dobec M, Bossart W, Kaeppeli F, et al. Serology and serum DNA detection in shingles. Swiss Med Weekly 2008; 138: 47-51.
36. Sauerbrei A, Eichhorn U, Schacke M, et al. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31-36.
37. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200: 1068-1077.
38. Malavige GN, Rohanachandra LT, Jones L, et al. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br J Cancer 2010; 102: 727-730.
39. Birlea M, Arendt G, Orhan E, et al. Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J Neurol Sci 2011; 304: 22-24.